[Possible role of alkylphosphocholines in retinal reattachment surgery].
BACKGROUND
Proliferative vitreoretinopathy (PVR) is a major complication after retinal detachment surgery, but there is no established pharmacotherapy available to control the cell biology of the disease. The aim of this study was to investigate the role of alkylphosphocholines [APCs; erucylphosphocholine (ErPC) was used in this study], novel pharmacologic substances with antiproliferative properties, on intraretinal proliferation initiated by experimental retinal detachment in a well-established in vivo model.


METHODS
Retinal detachments were created in adult pigmented rabbits. ErPC was injected intravitreally on either day 1 or day 2 after detachment. Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) was injected on day 3. Following fixation, retinas were triple-labelled with anti-BrdU (proliferation marker), Isolectin B4 (retinal microglia marker), and anti-vimentin (retinal Mueller glia cell marker). The number of anti-BrdU-labelled cells per millimeter of retina was determined from sections imaged by laser scanning confocal microscopy. Toxicity was assessed by light and electron microscopy.


RESULTS
A single intravitreal injection of ErPC had a significant effect on reducing the number of proliferating non-neural retinal cells on day 3 after experimental retinal detachment in the rabbit. Injection of ErPC on day 1 was more effective than when given on day 2. No evidence of toxicity was observed in the retina on day 3 for any of the conditions.


CONCLUSIONS
APCs are novel pharmacologic substances that significantly inhibited intraretinal proliferation after experimental retinal detachment in this in vivo model. They could be considered as an adjunct therapy at the time of retinal reattachment surgery to potentially prevent proliferative vitreoretinal diseases such as PVR. However, long-term toxicity studies must be performed before APCs can be considered for clinical application.
Eibl
K H
KH
Augenklinik der Ludwig-Maximilians-Universität, Mathildenstrasse 8, 80336, München. Kirsten.Eibl@med.uni-muenchen.de
Lewis
G P
GP
Betts
K
K
Linberg
K A
KA
Gandorfer
A
A
Fisher
S K
SK
Kampik
A
A
D000818:Animals; D005240:Feasibility Studies; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011817:Rabbits; D012163:Retinal Detachment / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome; D014821:Vitrectomy / Q000009:adverse effects*; D018630:Vitreoretinopathy, Proliferative / Q000209:etiology* / Q000473:pathology* / Q000517:prevention & control*
D010767:Phosphorylcholine; C075010:erucylphosphocholine